Project description
New detection technology to find the pathogens' Achilles heel
A new pathogen detection approach is urgently needed. There is a high market demand as critical test results obtained by standard procedure are often too late, particularly in the case of antibiotic resistance. Via EU-funding, Biotrack BV will develop an innovative solution for the quick, cost-effective detection and antibiotic sensitivity analysis of pathogens in any biological samples. This new platform will enable fast detection (between 0.5 - 4 hours). It has a user-friendly approach combining multiple capabilities for analysis of different kinds of pathogens: bacteria, virus, yeasts. Furthermore, assessment also includes drug susceptibility testing. This solution provides flexibility for organisation of services with its mobile application as well as privacy and decision-making tools.
Objective
Biotrack is a SME focused on the development and commercialization of novel microbial detection technology to achieve real time and actionable diagnostics. Our technology is covered with a solid patent portfolio.
We have identified a high market need for new pathogen detection techniques due to 2 main reasons: A) Dependency on standard microbiological protocols might delay early diagnosis; B) Growing demand for research and innovation, and a better quality and patient-centered technology due to the dramatic spread of antibiotic-resistant infections.
Biotrack's innovative solution, Biotrack-MED, is a micro-laboratory capability solution for the rapid detection, identification and antibiotic susceptibility testing of pathogens in any biological sample. Biotrack-MED is a fast and effective user-adaptable solution that combines multiple analytical principles for microbial identification and antibiotic pre-screening (total operative time: 0,5-4 hours), and it's capable of analyzing any microorganism (bacteria, virus, yeast). Our solution can be placed anywhere (includes a complementary mobile app) and it is equipped with state-of-the-art privacy and decision-making tools. Biotrack-MED offers a cost-effective low-cost substitution (50% saving) of traditional laboratories, and it does not require any skilled personnel to be used.
Considering the advantages of our unique healthcare solution, our expected customers in the EU are public and private hospitals and clinics. We have estimated that 5 years after start of commercialization we will reach a ROI of 5.8.
Fields of science
- social sciencessociologydemographymortality
- medical and health sciencesclinical medicinesurgery
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
8934 CJ LEEUWARDEN
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.